138 related articles for article (PubMed ID: 27181575)
41. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
Ali S; Leveque V; Le Pogam S; Ma H; Philipp F; Inocencio N; Smith M; Alker A; Kang H; Najera I; Klumpp K; Symons J; Cammack N; Jiang WR
Antimicrob Agents Chemother; 2008 Dec; 52(12):4356-69. PubMed ID: 18838588
[TBL] [Abstract][Full Text] [Related]
42. Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA.
Lam AM; Espiritu C; Bansal S; Micolochick Steuer HM; Zennou V; Otto MJ; Furman PA
J Virol; 2011 Dec; 85(23):12334-42. PubMed ID: 21957306
[TBL] [Abstract][Full Text] [Related]
43. Optimization of potency and pharmacokinetics of tricyclic indole derived inhibitors of HCV NS5B polymerase. Identification of ester prodrugs with improved oral pharmacokinetics.
Venkatraman S; Velazquez F; Gavalas S; Wu W; Chen KX; Nair AG; Bennett F; Huang Y; Pinto P; Jiang Y; Selyutin O; Vibulbhan B; Zeng Q; Lesburg C; Duca J; Heimark L; Huang HC; Agrawal S; Jiang CK; Ferrari E; Li C; Kozlowski J; Rosenblum S; Shih NY; Njoroge FG
Bioorg Med Chem; 2014 Jan; 22(1):447-58. PubMed ID: 24275348
[TBL] [Abstract][Full Text] [Related]
44. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.
Shi N; Hiraga N; Imamura M; Hayes CN; Zhang Y; Kosaka K; Okazaki A; Murakami E; Tsuge M; Abe H; Aikata H; Takahashi S; Ochi H; Tateno-Mukaidani C; Yoshizato K; Matsui H; Kanai A; Inaba T; McPhee F; Gao M; Chayama K
Gut; 2013 Jul; 62(7):1055-61. PubMed ID: 23322441
[TBL] [Abstract][Full Text] [Related]
45. The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.
Bobardt M; Ramirez CM; Baum MM; Ure D; Foster R; Gallay PA
PLoS One; 2021; 16(5):e0251934. PubMed ID: 34014993
[TBL] [Abstract][Full Text] [Related]
46. Bifunctional aryloxyphosphoramidate prodrugs of 2'-C-Me-uridine: synthesis and anti-HCV activity.
Maiti M; Gao LJ; Huang C; Ptak RG; Murray MG; De Jonghe S; Herdewijn P
Org Biomol Chem; 2016 Sep; 14(37):8743-8757. PubMed ID: 27714209
[TBL] [Abstract][Full Text] [Related]
47. Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates.
Rajyaguru S; Yang H; Martin R; Miller MD; Mo H
Antiviral Res; 2013 Nov; 100(2):328-36. PubMed ID: 24013002
[TBL] [Abstract][Full Text] [Related]
48. Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
Mengshetti S; Zhou L; Sari O; De Schutter C; Zhang H; Cho JH; Tao S; Bassit LC; Verma K; Domaoal RA; Ehteshami M; Jiang Y; Ovadia R; Kasthuri M; Ollinger Russell O; McBrayer T; Whitaker T; Pattassery J; Pascual ML; Uher L; Lin BY; Lee S; Amblard F; Coats SJ; Schinazi RF
J Med Chem; 2019 Feb; 62(4):1859-1874. PubMed ID: 30653317
[TBL] [Abstract][Full Text] [Related]
49. Discovery of Novel Nucleotide Prodrugs with Improved Potency Against HCV Variants Carrying NS5B S282T Mutation.
Zhen L; Dai L; Wen X; Yao L; Jin X; Yang XW; Zhao W; Yu SQ; Yuan H; Wang G; Sun H
J Med Chem; 2017 Jul; 60(14):6077-6088. PubMed ID: 28650160
[TBL] [Abstract][Full Text] [Related]
50. Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.
Murakami E; Bao H; Ramesh M; McBrayer TR; Whitaker T; Micolochick Steuer HM; Schinazi RF; Stuyver LJ; Obikhod A; Otto MJ; Furman PA
Antimicrob Agents Chemother; 2007 Feb; 51(2):503-9. PubMed ID: 17101674
[TBL] [Abstract][Full Text] [Related]
51. The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture.
Klumpp K; Lévêque V; Le Pogam S; Ma H; Jiang WR; Kang H; Granycome C; Singer M; Laxton C; Hang JQ; Sarma K; Smith DB; Heindl D; Hobbs CJ; Merrett JH; Symons J; Cammack N; Martin JA; Devos R; Nájera I
J Biol Chem; 2006 Feb; 281(7):3793-9. PubMed ID: 16316989
[TBL] [Abstract][Full Text] [Related]
52. Design and synthesis of novel carbocyclic versions of 2'-spirocyclopropyl ribonucleosides as potent anti-HCV agents.
Oh CH; Kim E; Hong JH
Nucleosides Nucleotides Nucleic Acids; 2011 Jun; 30(6):423-39. PubMed ID: 21780908
[TBL] [Abstract][Full Text] [Related]
53. Discovery of N-(4'-(indol-2-yl)phenyl)sulfonamides as novel inhibitors of HCV replication.
Chen G; Ren H; Turpoff A; Arefolov A; Wilde R; Takasugi J; Khan A; Almstead N; Gu Z; Komatsu T; Freund C; Breslin J; Colacino J; Hedrick J; Weetall M; Karp GM
Bioorg Med Chem Lett; 2013 Jul; 23(13):3942-6. PubMed ID: 23683596
[TBL] [Abstract][Full Text] [Related]
54. Exploration of the in vitro antiviral activity of a series of new pyrimidine analogues on the replication of HIV and HCV.
Jafar NN; Al-Masoudi NA; Baqir SJ; Leyssen P; Pannecouque C
Antivir Chem Chemother; 2012 Sep; 23(3):103-12. PubMed ID: 23010622
[TBL] [Abstract][Full Text] [Related]
55. Discovery of pyrimidine nucleoside dual prodrugs and pyrazine nucleosides as novel anti-HCV agents.
Guo S; Xu M; Guo Q; Zhu F; Jiang X; Xie Y; Shen J
Bioorg Med Chem; 2019 Mar; 27(5):748-759. PubMed ID: 30683552
[TBL] [Abstract][Full Text] [Related]
56. 2-Heteroarylimino-5-arylidene-4-thiazolidinones as a new class of non-nucleoside inhibitors of HCV NS5B polymerase.
Küçükgüzel I; Satılmış G; Gurukumar KR; Basu A; Tatar E; Nichols DB; Talele TT; Kaushik-Basu N
Eur J Med Chem; 2013 Nov; 69():931-41. PubMed ID: 24161679
[TBL] [Abstract][Full Text] [Related]
57. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
[TBL] [Abstract][Full Text] [Related]
58. HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus.
Kneteman NM; Howe AY; Gao T; Lewis J; Pevear D; Lund G; Douglas D; Mercer DF; Tyrrell DL; Immermann F; Chaudhary I; Speth J; Villano SA; O'Connell J; Collett M
Hepatology; 2009 Mar; 49(3):745-52. PubMed ID: 19072827
[TBL] [Abstract][Full Text] [Related]
59. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
[TBL] [Abstract][Full Text] [Related]
60. Concise syntheses and HCV NS5B polymerase inhibition of (2'R)-3 and (2'S)-2'-ethynyluridine-10 and related nucleosides.
Bennett F; Buevich AV; Huang HC; Girijavallabhan V; Kerekes AD; Huang Y; Malikzay A; Smith E; Ferrari E; Senior M; Osterman R; Wang L; Wang J; Pu H; Truong QT; Tawa P; Bogen SL; Davies IW; Weber AE
Bioorg Med Chem Lett; 2017 Dec; 27(23):5349-5352. PubMed ID: 29056248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
